旨在评估亚洲局部晚期或转移性尿路上皮癌患者的人口统计学和临床​​特征、治疗模式和生活质量。数据来自 Adelphi Real World Metastatic Urothelial Carcinoma Drug Specific Programme™，这是一项针对医学肿瘤学家的横断面调查/沙特阿拉伯、韩国、台湾和土耳其的泌尿科医生及其成年患者。患者报告的探索性结果包括 EQ-5D 视觉模拟量表、欧洲癌症研究和治疗组织全球健康患者生活质量问卷以及简要疼痛量表。分析是描述性的。总体而言，175 名医生报告了 988 名患者的数据。患者平均年龄（标准差）为 66.3 (10.8) 岁，77% 为男性，82% 诊断时患有膀胱肿瘤。在接受一线 (n = 988)、二线 (n = 290) 和三线 (n = 87) 治疗的患者中，分别有 81%、35% 和 59% 接受化疗，17%、63% 接受化疗、34% 分别接受了程序性细胞死亡蛋白 1/配体 1 抑制剂。患者报告（n = 319）平均（标准差）EQ-5D视觉模拟量表评分为51.8（15.6），欧洲癌症研究与治疗组织患者生活质量问卷全球健康状况评分为44.6（19.9），简短疼痛量表评分为 6.5（1.9；n = 315）。局部晚期或转移性尿路上皮癌最常见的一线和二线治疗分别是化疗和程序性细胞死亡蛋白 1/配体抑制剂。在三线，10% 的患者仅接受了最佳支持治疗，这凸显了对有效三线治疗方案的需求尚未得到满足。所有地区的患者均报告生活质量受损。© 2024 作者。约翰·威利出版的《国际泌尿外科杂志》

To evaluate demographic and clinical characteristics, treatment patterns, and quality of life in patients with locally advanced or metastatic urothelial carcinoma in Asia.Data were drawn from the Adelphi Real World Metastatic Urothelial Carcinoma Disease Specific Programme™, a cross-sectional survey of medical oncologists/urologists and their adult patients in Saudi Arabia, South Korea, Taiwan, and Turkey. Exploratory patient-reported outcomes included the EQ-5D visual analog scale, European Organisation for Research and Treatment of Cancer Quality of Life of Patient Questionnaire global health, and Brief Pain Inventory. Analyses were descriptive.Overall, 175 physicians reported data for 988 patients. Mean (standard deviation) patient age was 66.3 (10.8) years, 77% were men, and 82% had bladder tumors at diagnosis. Of patients receiving first- (n = 988), second- (n = 290), and third-line (n = 87) treatments, 81%, 35%, and 59% received chemotherapy, respectively, and 17%, 63%, and 34% received programmed cell death protein 1/ligand 1 inhibitors, respectively. Patient-reported (n = 319) mean (standard deviation) EQ-5D visual analog scale score was 51.8 (15.6), European Organisation for Research and Treatment of Cancer Quality of Life of Patient Questionnaire global health status score was 44.6 (19.9), and Brief Pain Inventory score was 6.5 (1.9; n = 315).The most common first- and second-line treatments for locally advanced or metastatic urothelial carcinoma were chemotherapy and programmed cell death protein 1/ligand inhibitors, respectively. At third line, 10% of patients received best supportive care alone, underscoring an unmet need for effective third-line treatment options. Patients in all regions reported quality-of-life impairment.© 2024 The Author(s). International Journal of Urology published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Urological Association.